Trial Profile

An Open-Label Extension Study to Evaluate the Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 24 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Aug 2022 Results assessing efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis from clinical study RESET (NCT02187003) and its OLE (NCT02433158) published in the Blood
07 Dec 2020 Post hoc analyses of the Phase 3 RESET trial and the subsequent pre-planned analysis of the OLE trial published in the GlycoMimetics Media Release.
07 Dec 2020 According to a GlycoMimetics media release, data from this study were presented by by University of California Davis's Theodore Wun at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com